Predicting Time to Delivery in Hypertensive Disorders: Assessing PlGF and sFlt-1 with the Novel Parameter ‘Mtp-Multiples of a Normal Term Placenta’

Predicting Time to Delivery in Hypertensive Disorders: Assessing PlGF and sFlt-1 with the Novel Parameter ‘Mtp-Multiples of a Normal Term Placenta’

<b>Background:</b> Imbalanced angiogenesis is characteristic of normal placental maturation but it also signals placental dysfunction, underlying hypertensive disorders during pregnancy. This study aimed to investigate the relationship between angiogenic placental aging, measured by mark...

Full description

Bibliographic Details
Main Authors:	Valentina Giardini, Alice Angela Francesca Santagati, Elisabetta Marelli, Marco Casati, Anna Cantarutti, Patrizia Vergani
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Series:	Journal of Clinical Medicine
Subjects:	placental growth factor (PlGF) soluble fms-like tyrosine kinase (sFlt-1) hypertensive disorders of pregnancy placental aging timing of delivery angiogenesis
Online Access:	https://www.mdpi.com/2077-0383/13/7/1899

Similar Items

sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics
by: Viktorija Tarasevičienė, et al.
Published: (2016-01-01)

sFLT1, PlGF, the sFLT1/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies—A Review of the Literature
by: Ioakeim Sapantzoglou, et al.
Published: (2023-06-01)

Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian populationAJOG Global Reports at a Glance
by: Namrata Kumar, MD, MRCOG, EFOG, FACOG, et al.
Published: (2023-05-01)

Efficiency of sFlt-1/PlGF Ratio in Preeclampsia Diagnosis
by: Anca-Florina Tataru-Copos, et al.
Published: (2022-09-01)

A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia
by: Vivek Pant, et al.
Published: (2019-07-01)

The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19
by: Katarzyna Kosinska-Kaczynska, et al.
Published: (2023-01-01)

The sFlt-1/PlGF Ratio at 12, 24, and 32 Weeks Gestation in Twin Pregnancies as a Predictor of Placental Dysfunction
by: Elena Satorres-Pérez, et al.
Published: (2024-03-01)

sFlt-1, Not PlGF, Is Related to Twin Gestation Choronicity in the First and Third Trimesters of Pregnancy
by: Szymon Kozłowski, et al.
Published: (2021-06-01)

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients
by: Kamil Pluta, et al.
Published: (2024-01-01)

The role of sFlt1/PlGF ratio in the assessment of preeclampsia and pregnancy-related hypertensive disorders
by: Jonathan Baert, et al.
Published: (2021-07-01)

Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission
by: Lukas Penka, et al.
Published: (2020-04-01)

sFlt-1 in Chronic Kidney Disease: Friend or Foe?
by: Masaru Matsui, et al.
Published: (2022-11-01)

Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia
by: Laura Ehrlich, et al.
Published: (2017-04-01)

sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates
by: Jacek Witwicki, et al.
Published: (2021-08-01)

Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia
by: Nataliia Sergeevna Karpova, et al.
Published: (2023-04-01)

Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia: PREPARE cohort study
by: M. Wind, et al.
Published: (2022-12-01)

Reduced expression in preterm birth of sFLT-1 and PlGF with a high sFLT-1/PlGF ratio in extracellular vesicles suggests a potential biomarker
by: Sama Hussein, et al.
Published: (2022-12-01)

Predicting Preeclampsia Pregnancy Termination Time Using sFlt-1
by: Hiroaki Tanaka, et al.
Published: (2022-06-01)

Correlation between uterine artery Doppler and the sFlt-1/PlGF ratio in different phenotypes of placental dysfunction
by: Vesna Fabjan-Vodusek, et al.
Published: (2019-01-01)

PlGF Immunological Impact during Pregnancy
by: Loredana Albonici, et al.
Published: (2020-11-01)

The Current Role of the sFlt-1/PlGF Ratio and the Uterine–Umbilical–Cerebral Doppler Ultrasound in Predicting and Monitoring Hypertensive Disorders of Pregnancy: An Update with a Review of the Literature
by: Cristian Nicolae Chirilă, et al.
Published: (2023-08-01)

Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal movement at or after 36+ 0 weeks gestation
by: Lindsay Armstrong-Buisseret, et al.
Published: (2018-10-01)

Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt‐1 (Soluble fms‐Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio
by: Cecilia Villalaín, et al.
Published: (2020-04-01)

Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies
by: Alice Hoeller, et al.
Published: (2017-04-01)

Values of serum sFlt-1, PLGF levels, and sFlt-1/PLGF ratio in diagnosis and prognosis evaluation of preeclamptic patients
by: Xiaohe Zhu, et al.
Published: (2020-10-01)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers
by: Carmen Garrido-Giménez, et al.
Published: (2023-01-01)

Maternal Serum Angiogenic Profile and Its Correlations with Ultrasound Parameters and Perinatal Results in Normotensive and Preeclamptic Pregnancies Complicated by Fetal Growth Restriction
by: Weronika Dymara-Konopka, et al.
Published: (2023-06-01)

Predictive Value Analysis of Serum sFlt-1 and PLGF Levels/Ratio in Preeclampsia
by: Shuyuan Xue, et al.
Published: (2022-09-01)

Associations between Maternal sFlt-1/PlGF Ratio and Perinatal and Neonatal Outcomes in Newborns Born to Mothers with Preeclampsia
by: Hyo Ju Yang, et al.
Published: (2023-08-01)

Predictive value of the sFlt-1/PlGF ratio for preeclampsia in twin pregnancies: a retrospective study
by: Satoshi Shinohara, et al.
Published: (2021-10-01)

The Impact of Increased Maternal sFlt-1/PlGF Ratio on Motor Outcome of Preterm Infants
by: Lisa Middendorf, et al.
Published: (2022-06-01)

Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction
by: Weronika Dymara-Konopka, et al.
Published: (2023-01-01)

Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection
by: Valentina Giardini, et al.
Published: (2021-11-01)

Pro-angiogenic therapeutics for preeclampsia
by: Adrian C. Eddy, et al.
Published: (2018-08-01)

Diagnostic Accuracy of Different Soluble fms-Like Tyrosine Kinase 1 and Placental Growth Factor Cut-Off Values in the Assessment of Preterm and Term Preeclampsia: A Gestational Age Matched Case-Control Study
by: Evelyn A. Huhn, et al.
Published: (2018-11-01)

Angiogenic factors (sFlt-1, PlGF) in twin pregnancy with placentaassociated complications
by: M. A. Kurtser, et al.
Published: (2022-11-01)

Progesterone Induced Blocking Factor Reduces Hypertension and Placental Mitochondrial Dysfunction in Response to sFlt-1 during Pregnancy
by: Evangeline Deer, et al.
Published: (2021-10-01)

Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment
by: Lei Li, et al.
Published: (2020-02-01)

Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
by: Roxanne Hastie, et al.
Published: (2022-08-01)

PAPP‐A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia
by: Rugina I. Neuman, et al.
Published: (2020-10-01)